Ranibizumab plus Verteporfin Photodynamic Therapy in Neovascular Age-Related Macular Degeneration: 1...
Ranibizumab plus Verteporfin Photodynamic Therapy in Neovascular Age-Related Macular Degeneration: 12 Months of Retreatment and Vision Outcomes from a Randomized Study
About this item
Full title
Author / Creator
Publisher
Basel, Switzerland: S. Karger AG
Journal title
Language
English
Formats
Publication information
Publisher
Basel, Switzerland: S. Karger AG
Subjects
More information
Scope and Contents
Contents
Purpose: To investigate the injection frequency and visual acuity (VA) outcomes with combination therapy (ranibizumab plus verteporfin photodynamic therapy, PDT) versus monotherapy (ranibizumab). Methods: A total of 40 patients with exudative age-related macular degeneration were randomized 1:1 to ranibizumab 0.3 mg plus single standard verteporfin...
Alternative Titles
Full title
Ranibizumab plus Verteporfin Photodynamic Therapy in Neovascular Age-Related Macular Degeneration: 12 Months of Retreatment and Vision Outcomes from a Randomized Study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_karger_primary_367603
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_karger_primary_367603
Other Identifiers
ISSN
0030-3755
E-ISSN
1423-0267
DOI
10.1159/000367603
